AstraZeneca ( NASDAQ: AZN) and Daiichi Sankyo have received priority review from the FDA for their supplemental marketing application for Enhertu in combination with pertuzumab, marketed by Roche ( ...

The FDA granted priority review for trastuzumab deruxtecan in combination with pertuzumab for first-line treatment of adults ...

Enhertu plus pertuzumab granted Priority Review in US as 1st-line treatment for patients with HER2-positive metastatic breast cancer: Cambridge, UK Thursday, September 25, 2025, 0 ...

The U.S. Food and Drug Administration (FDA) has granted priority review to a supplemental biologics license application for ...

The FDA has granted priority review to the supplemental biologics license application (sBLA) of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the first-line treatment of patients with ...

Trastuzumab deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate currently marketed under the brand name Enhertu as a second-line therapy for HER2-positive metastatic breast ...

Jiangsu Hengrui Pharmaceuticals’ dealmaking spree rolls on, with a potential $1.1 billion transaction on a rival to AstraZeneca and Daiichi Sankyo’s blockbuster Enhertu being the latest addition.

The deal involves an upfront payment of $18 million, followed by regulatory and commercial milestone payments of up to $1.093 ...

The pharmaceutical sector has seen a flurry of new deals, partnerships, and drug launches this week, presenting potential ...

AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application for Enhertu plus pertuzumab has been accepted for Priority Review b ...

The Organisation for Economic Co-operation and Development marginally raised its 2025 growth projection for the UK economy to 1.4% from 1.3%, noting that front‑loading ahead of higher tariffs globally ...

Patients on Enhertu and Perjeta lived more than three years without disease progression compared to just over two years on Perjeta, Herceptin, and chemo.